ID   NCOA1_HUMAN             Reviewed;        1441 AA.
AC   Q15788; O00150; O43792; O43793; Q13071; Q13420; Q2T9G5; Q53SX3;
AC   Q6GVI5; Q7KYV3;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   11-SEP-2007, sequence version 3.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Nuclear receptor coactivator 1;
DE            Short=NCoA-1;
DE            EC=2.3.1.48;
DE   AltName: Full=Class E basic helix-loop-helix protein 74;
DE            Short=bHLHe74;
DE   AltName: Full=Protein Hin-2;
DE   AltName: Full=RIP160;
DE   AltName: Full=Renal carcinoma antigen NY-REN-52;
DE   AltName: Full=Steroid receptor coactivator 1;
DE            Short=SRC-1;
GN   Name=NCOA1; Synonyms=BHLHE74, SRC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INTERACTION WITH GTF2B, AND
RP   VARIANTS LYS-457; LYS-466; PRO-474; THR-591; ALA-685; PHE-999 AND
RP   THR-1154.
RX   PubMed=8754792; DOI=10.1210/endo.137.8.8754792;
RA   Takeshita A., Yen P.M., Misiti S., Cardona G.R., Liu Y., Chin W.W.;
RT   "Molecular cloning and properties of a full-length putative thyroid
RT   hormone receptor coactivator.";
RL   Endocrinology 137:3594-3597(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF 636-LEU-LEU-637; 693-LEU-LEU-694 AND
RP   752-LEU-LEU-753.
RX   PubMed=9427757; DOI=10.1093/emboj/17.1.232;
RA   Kalkhoven E., Valentine J.E., Heery D.M., Parker M.G.;
RT   "Isoforms of steroid receptor coactivator 1 differ in their ability to
RT   potentiate transcription by the oestrogen receptor.";
RL   EMBO J. 17:232-243(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LYS-457; LYS-466;
RP   PRO-474; THR-591; ALA-685; PHE-999 AND THR-1154.
RC   TISSUE=Heart muscle, and Skeletal muscle;
RX   PubMed=9575154; DOI=10.1074/jbc.273.20.12101;
RA   Onate S.A., Boonyaratanakornkit V., Spencer T.E., Tsai S.Y.,
RA   Tsai M.-J., Edwards D.P., O'Malley B.W.;
RT   "The steroid receptor coactivator-1 contains multiple receptor
RT   interacting and activation domains that cooperatively enhance the
RT   activation function 1 (AF1) and AF2 domains of steroid receptors.";
RL   J. Biol. Chem. 273:12101-12108(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-1238 AND SER-1272.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 363-1441 (ISOFORM 1), FUNCTION,
RP   INTERACTION WITH ESR1; RXRA; GCCR; PGR AND THRA, AND VARIANTS LYS-457;
RP   LYS-466; PRO-474; THR-591; ALA-685; ALA-794; PHE-999 AND THR-1154.
RX   PubMed=7481822; DOI=10.1126/science.270.5240.1354;
RA   Onate S.A., Tsai S.Y., Tsai M.-J., O'Malley B.W.;
RT   "Sequence and characterization of a coactivator for the steroid
RT   hormone receptor superfamily.";
RL   Science 270:1354-1357(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 865-1441 (ISOFORM 2).
RX   PubMed=11831720; DOI=10.1006/viro.1995.1161;
RA   Raineri I., Soler M., Senn H.-P.;
RT   "Analysis of human immunodeficiency virus type 1 promoter insertion in
RT   vivo.";
RL   Virology 208:359-364(1995).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 868-1441 (ISOFORM 2), CHROMOSOMAL
RP   TRANSLOCATION WITH PAX3, AND TISSUE SPECIFICITY.
RX   PubMed=15313887; DOI=10.1158/0008-5472.CAN-04-0844;
RA   Wachtel M., Dettling M., Koscielniak E., Stegmaier S., Treuner J.,
RA   Simon-Klingenstein K., Buehlmann P., Niggli F.K., Schaefer B.W.;
RT   "Gene expression signatures identify rhabdomyosarcoma subtypes and
RT   detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.";
RL   Cancer Res. 64:5539-5545(2004).
RN   [11]
RP   IDENTIFICATION (ISOFORM 2), FUNCTION, AND ALTERNATIVE SPLICING.
RX   PubMed=9223431; DOI=10.1006/bbrc.1997.6911;
RA   Hayashi Y., Ohmori S., Ito T., Seo H.;
RT   "A splicing variant of steroid receptor coactivator-1 (SRC-1E): the
RT   major isoform of SRC-1 to mediate thyroid hormone action.";
RL   Biochem. Biophys. Res. Commun. 236:83-87(1997).
RN   [12]
RP   FUNCTION AS A HISTONE ACETYLTRANSFERASE, AND INTERACTION WITH PCAF.
RX   PubMed=9296499; DOI=10.1038/38304;
RA   Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J.,
RA   Mizzen C.A., McKenna N.J., Onate S.A., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Steroid receptor coactivator-1 is a histone acetyltransferase.";
RL   Nature 389:194-198(1997).
RN   [13]
RP   FUNCTION.
RX   PubMed=9223281; DOI=10.1073/pnas.94.15.7879;
RA   Jenster G., Spencer T.E., Burcin M.M., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Steroid receptor induction of gene transcription: a two-step model.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7879-7884(1997).
RN   [14]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [15]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10567404; DOI=10.1074/jbc.274.48.34283;
RA   Lee S.-K., Anzick S.L., Choi J.-E., Bubendorf L., Guan X.-Y.,
RA   Jung Y.-K., Kallioniemi O.-P., Kononen J., Trent J.M., Azorsa D.,
RA   Jhun B.-H., Cheong J.H., Lee Y.C., Meltzer P.S., Lee J.W.;
RT   "A nuclear factor ASC-2, as a cancer-amplified transcriptional
RT   coactivator essential for ligand-dependent transactivation by nuclear
RT   receptors in vivo.";
RL   J. Biol. Chem. 274:34283-34293(1999).
RN   [16]
RP   FUNCTION.
RX   PubMed=10449719; DOI=10.1073/pnas.96.17.9485;
RA   Liu Z., Wong J., Tsai S.Y., Tsai M.-J., O'Malley B.W.;
RT   "Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and
RT   receptor-dependent cell-free transcription of chromatin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9485-9490(1999).
RN   [17]
RP   PHOSPHORYLATION AT SER-372; SER-395; SER-517; SER-569; SER-1033;
RP   THR-1179 AND SER-1185.
RX   PubMed=10660621; DOI=10.1074/jbc.275.6.4475;
RA   Rowan B.G., Weigel N.L., O'Malley B.W.;
RT   "Phosphorylation of steroid receptor coactivator-1. Identification of
RT   the phosphorylation sites and phosphorylation through the mitogen-
RT   activated protein kinase pathway.";
RL   J. Biol. Chem. 275:4475-4483(2000).
RN   [18]
RP   INTERACTION WITH COPS5.
RX   PubMed=10722692; DOI=10.1074/jbc.275.12.8540;
RA   Chauchereau A., Georgiakaki M., Perrin-Wolff M., Milgrom E.,
RA   Loosfelt H.;
RT   "JAB1 interacts with both the progesterone receptor and SRC-1.";
RL   J. Biol. Chem. 275:8540-8548(2000).
RN   [19]
RP   INTERACTION WITH NCOA2.
RX   PubMed=10594042; DOI=10.1128/MCB.20.1.402-415.2000;
RA   Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H.,
RA   Poellinger L.;
RT   "Redox-regulated recruitment of the transcriptional coactivators CREB-
RT   binding protein and SRC-1 to hypoxia-inducible factor 1alpha.";
RL   Mol. Cell. Biol. 20:402-415(2000).
RN   [20]
RP   INTERACTION WITH DDX5.
RX   PubMed=11250900; DOI=10.1093/emboj/20.6.1341;
RA   Watanabe M., Yanagisawa J., Kitagawa H., Takeyama K., Ogawa S.,
RA   Arao Y., Suzawa M., Kobayashi Y., Yano T., Yoshikawa H., Masuhiro Y.,
RA   Kato S.;
RT   "A subfamily of RNA-binding DEAD-box proteins acts as an estrogen
RT   receptor alpha coactivator through the N-terminal activation domain
RT   (AF-1) with an RNA coactivator, SRA.";
RL   EMBO J. 20:1341-1352(2001).
RN   [21]
RP   INTERACTION WITH STAT3.
RX   PubMed=11773079; DOI=10.1074/jbc.M111486200;
RA   Giraud S., Bienvenu F., Avril S., Gascan H., Heery D.M., Coqueret O.;
RT   "Functional interaction of STAT3 transcription factor with the
RT   coactivator NcoA/SRC1a.";
RL   J. Biol. Chem. 277:8004-8011(2002).
RN   [22]
RP   INTERACTION WITH PRMT2.
RX   PubMed=12039952; DOI=10.1074/jbc.M201053200;
RA   Qi C., Chang J., Zhu Y., Yeldandi A.V., Rao S.M., Zhu Y.-J.;
RT   "Identification of protein arginine methyltransferase 2 as a
RT   coactivator for estrogen receptor alpha.";
RL   J. Biol. Chem. 277:28624-28630(2002).
RN   [23]
RP   INTERACTION WITH STAT6.
RX   PubMed=12138096; DOI=10.1074/jbc.M203556200;
RA   Litterst C.M., Pfitzner E.;
RT   "An LXXLL motif in the transactivation domain of STAT6 mediates
RT   recruitment of NCoA-1/SRC-1.";
RL   J. Biol. Chem. 277:36052-36060(2002).
RN   [24]
RP   SUMOYLATION AT LYS-732 AND LYS-774, UBIQUITINATION, AND MUTAGENESIS OF
RP   LYS-732; LYS-774; LYS-800; LYS-846 AND LYS-1378.
RX   PubMed=12529333; DOI=10.1074/jbc.M207148200;
RA   Chauchereau A., Amazit L., Quesne M., Guiochon-Mantel A., Milgrom E.;
RT   "Sumoylation of the progesterone receptor and of the steroid receptor
RT   coactivator SRC-1.";
RL   J. Biol. Chem. 278:12335-12343(2003).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH STAT5A AND STAT5B.
RX   PubMed=12954634; DOI=10.1074/jbc.M303644200;
RA   Litterst C.M., Kliem S., Marilley D., Pfitzner E.;
RT   "NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the
RT   FDL motif in the alpha-helical region of the STAT5 transactivation
RT   domain.";
RL   J. Biol. Chem. 278:45340-45351(2003).
RN   [26]
RP   INTERACTION WITH NR3C1.
RX   PubMed=12917342; DOI=10.1128/MCB.23.17.6210-6220.2003;
RA   Hsiao P.W., Fryer C.J., Trotter K.W., Wang W., Archer T.K.;
RT   "BAF60a mediates critical interactions between nuclear receptors and
RT   the BRG1 chromatin-remodeling complex for transactivation.";
RL   Mol. Cell. Biol. 23:6210-6220(2003).
RN   [27]
RP   INTERACTION WITH UBE2L3.
RX   PubMed=15367689; DOI=10.1128/MCB.24.19.8716-8726.2004;
RA   Verma S., Ismail A., Gao X., Fu G., Li X., O'Malley B.W., Nawaz Z.;
RT   "The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for
RT   steroid hormone receptors.";
RL   Mol. Cell. Biol. 24:8716-8726(2004).
RN   [28]
RP   INTERACTION WITH PSMB9.
RX   PubMed=16957778; DOI=10.1038/sj.emboj.7601306;
RA   Zhang H., Sun L., Liang J., Yu W., Zhang Y., Wang Y., Chen Y., Li R.,
RA   Sun X., Shang Y.;
RT   "The catalytic subunit of the proteasome is engaged in the entire
RT   process of estrogen receptor-regulated transcription.";
RL   EMBO J. 25:4223-4233(2006).
RN   [29]
RP   INTERACTION WITH ASXL1.
RX   PubMed=16606617; DOI=10.1074/jbc.M512616200;
RA   Cho Y.S., Kim E.J., Park U.H., Sin H.S., Um S.J.;
RT   "Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts
RT   as a ligand-dependent coactivator for retinoic acid receptor.";
RL   J. Biol. Chem. 281:17588-17598(2006).
RN   [30]
RP   INTERACTION WITH TTLL5.
RC   TISSUE=Testis;
RX   PubMed=17116691; DOI=10.1128/MCB.01360-06;
RA   He Y., Simons S.S. Jr.;
RT   "STAMP, a novel predicted factor assisting TIF2 actions in
RT   glucocorticoid receptor-mediated induction and repression.";
RL   Mol. Cell. Biol. 27:1467-1485(2007).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [33]
RP   INTERACTION WITH RXRA.
RX   PubMed=19786558; DOI=10.1124/mol.109.057000;
RA   Cho Y., Noshiro M., Choi M., Morita K., Kawamoto T., Fujimoto K.,
RA   Kato Y., Makishima M.;
RT   "The basic helix-loop-helix proteins differentiated embryo chondrocyte
RT   (DEC) 1 and DEC2 function as corepressors of retinoid X receptors.";
RL   Mol. Pharmacol. 76:1360-1369(2009).
RN   [34]
RP   INTERACTION WITH PRMT6.
RX   PubMed=20047962; DOI=10.1093/nar/gkp1203;
RA   Harrison M.J., Tang Y.H., Dowhan D.H.;
RT   "Protein arginine methyltransferase 6 regulates multiple aspects of
RT   gene expression.";
RL   Nucleic Acids Res. 38:2201-2216(2010).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-395, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22; SER-372; SER-395;
RP   SER-698 AND SER-1372, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [37]
RP   INTERACTION WITH TRIP4.
RX   PubMed=25219498; DOI=10.1016/j.molcel.2014.08.007;
RA   Yoo H.M., Kang S.H., Kim J.Y., Lee J.E., Seong M.W., Lee S.W.,
RA   Ka S.H., Sou Y.S., Komatsu M., Tanaka K., Lee S.T., Noh D.Y.,
RA   Baek S.H., Jeon Y.J., Chung C.H.;
RT   "Modification of ASC1 by UFM1 is crucial for ERalpha transactivation
RT   and breast cancer development.";
RL   Mol. Cell 56:261-274(2014).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 623-710 IN COMPLEX WITH
RP   PPARG.
RX   PubMed=9744270; DOI=10.1038/25931;
RA   Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H.,
RA   Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V.;
RT   "Ligand binding and co-activator assembly of the peroxisome
RT   proliferator-activated receptor-gamma.";
RL   Nature 395:137-143(1998).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 687-696 IN COMPLEX WITH
RP   PPARA.
RX   PubMed=11698662; DOI=10.1073/pnas.241410198;
RA   Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B.,
RA   Collins J.L., Oplinger J.A., Kliewer S.A., Gampe R.T. Jr., McKee D.D.,
RA   Moore J.T., Willson T.M.;
RT   "Structural determinants of ligand binding selectivity between the
RT   peroxisome proliferator-activated receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:13919-13924(2001).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 686-700 IN COMPLEX WITH
RP   ESRRG.
RX   PubMed=11864604; DOI=10.1016/S1097-2765(02)00444-6;
RA   Greschik H., Wurtz J.-M., Sanglier S., Bourguet W., van Dorsselaer A.,
RA   Moras D., Renaud J.-P.;
RT   "Structural and functional evidence for ligand-independent
RT   transcriptional activation by the estrogen-related receptor 3.";
RL   Mol. Cell 9:303-313(2002).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 257-385 IN COMPLEX WITH
RP   795-808 OF STAT6.
RX   PubMed=14757047; DOI=10.1016/j.jmb.2003.12.057;
RA   Razeto A., Ramakrishnan V., Litterst C.M., Giller K., Griesinger C.,
RA   Carlomagno T., Lakomek N., Heimburg T., Lodrini M., Pfitzner E.,
RA   Becker S.;
RT   "Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif
RT   of the STAT6 transactivation domain.";
RL   J. Mol. Biol. 336:319-329(2004).
CC   -!- FUNCTION: Nuclear receptor coactivator that directly binds nuclear
CC       receptors and stimulates the transcriptional activities in a
CC       hormone-dependent fashion. Involved in the coactivation of
CC       different nuclear receptors, such as for steroids (PGR, GR and
CC       ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids
CC       (PPARs). Also involved in coactivation mediated by STAT3, STAT5A,
CC       STAT5B and STAT6 transcription factors. Displays histone
CC       acetyltransferase activity toward H3 and H4; the relevance of such
CC       activity remains however unclear. Plays a central role in creating
CC       multisubunit coactivator complexes that act via remodeling of
CC       chromatin, and possibly acts by participating in both chromatin
CC       remodeling and recruitment of general transcription factors.
CC       Required with NCOA2 to control energy balance between white and
CC       brown adipose tissues. Required for mediating steroid hormone
CC       response. Isoform 2 has a higher thyroid hormone-dependent
CC       transactivation activity than isoform 1 and isoform 3.
CC       {ECO:0000269|PubMed:10449719, ECO:0000269|PubMed:12954634,
CC       ECO:0000269|PubMed:7481822, ECO:0000269|PubMed:9223281,
CC       ECO:0000269|PubMed:9223431, ECO:0000269|PubMed:9296499,
CC       ECO:0000269|PubMed:9427757}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine.
CC   -!- SUBUNIT: Interacts with the methyltransferase CARM1 (By
CC       similarity). Interacts with NCOA6 and NCOA2. Interacts with the
CC       FDL motif of STAT5A and STAT5B. Interacts with the LXXLL motif of
CC       STAT6. Interacts with STAT3 following IL-6 stimulation. Interacts
CC       with the basal transcription factor GTF2B. Interacts with the
CC       histone acetyltransferases EP300 and CREBBP. Interacts with PCAF,
CC       COPS5, NR3C1 and TTLL5/STAMP. Interacts with PSMB9. Interacts with
CC       UBE2L3; they functionally interact to regulate progesterone
CC       receptor transcriptional activity. Interacts with PRMT2 and DDX5.
CC       Interacts with ASXL1. Interacts with PRMT6. Interacts (via LXXLL
CC       1, 2 and 3 motifs) with RORC (via AF-2 motif). Interacts in a
CC       ligand-dependent fashion with RXRA. Interacts with TRIP4.
CC       Interacts with NR4A3 (By similarity).
CC       {ECO:0000250|UniProtKB:P70365, ECO:0000269|PubMed:10567404,
CC       ECO:0000269|PubMed:10594042, ECO:0000269|PubMed:10722692,
CC       ECO:0000269|PubMed:11250900, ECO:0000269|PubMed:11698662,
CC       ECO:0000269|PubMed:11773079, ECO:0000269|PubMed:11864604,
CC       ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12138096,
CC       ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:12954634,
CC       ECO:0000269|PubMed:14757047, ECO:0000269|PubMed:15367689,
CC       ECO:0000269|PubMed:16606617, ECO:0000269|PubMed:16957778,
CC       ECO:0000269|PubMed:17116691, ECO:0000269|PubMed:19786558,
CC       ECO:0000269|PubMed:20047962, ECO:0000269|PubMed:25219498,
CC       ECO:0000269|PubMed:7481822, ECO:0000269|PubMed:8754792,
CC       ECO:0000269|PubMed:9296499, ECO:0000269|PubMed:9744270}.
CC   -!- INTERACTION:
CC       P59598:Asxl1 (xeno); NbExp=2; IntAct=EBI-455189, EBI-5743705;
CC       P03372:ESR1; NbExp=10; IntAct=EBI-455189, EBI-78473;
CC       P19785:Esr1 (xeno); NbExp=2; IntAct=EBI-455189, EBI-346765;
CC       Q63ZY3:KANK2; NbExp=4; IntAct=EBI-455189, EBI-2556193;
CC       P25799:Nfkb1 (xeno); NbExp=2; IntAct=EBI-455189, EBI-643958;
CC       Q13133:NR1H3; NbExp=15; IntAct=EBI-455189, EBI-781356;
CC       Q96RI1:NR1H4; NbExp=4; IntAct=EBI-455189, EBI-1250177;
CC       O75469:NR1I2; NbExp=5; IntAct=EBI-455189, EBI-3905991;
CC       P06536:Nr3c1 (xeno); NbExp=2; IntAct=EBI-455189, EBI-1187143;
CC       Q9BTK6:PAGR1; NbExp=4; IntAct=EBI-455189, EBI-2372223;
CC       P28065:PSMB9; NbExp=3; IntAct=EBI-455189, EBI-603300;
CC       P10276:RARA; NbExp=3; IntAct=EBI-455189, EBI-413374;
CC       P51449:RORC; NbExp=2; IntAct=EBI-455189, EBI-3908771;
CC       P19793:RXRA; NbExp=10; IntAct=EBI-455189, EBI-78598;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00981}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=SRC-1A, SRC1a;
CC         IsoId=Q15788-1; Sequence=Displayed;
CC       Name=2; Synonyms=SRC-1E, SRC1e;
CC         IsoId=Q15788-2; Sequence=VSP_011739;
CC         Note=Major form. Contains a domain at its C-terminus (1241-1399)
CC         that is able to mediate transactivation.;
CC       Name=3; Synonyms=SRC-1 (-Q);
CC         IsoId=Q15788-3; Sequence=VSP_011738;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:15313887, ECO:0000269|PubMed:9427757}.
CC   -!- DOMAIN: The C-terminal (1107-1441) part mediates the histone
CC       acetyltransferase (HAT) activity.
CC   -!- DOMAIN: Contains 7 Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. LXXLL
CC       motifs 3, 4 and 5 are essential for the association with nuclear
CC       receptors. LXXLL motif 7, which is not present in isoform 2,
CC       increases the affinity for steroid receptors in vitro.
CC   -!- PTM: Sumoylated; sumoylation increases its interaction with PGR
CC       and prolongs its retention in the nucleus. It does not prevent its
CC       ubiquitination and does not exert a clear effect on the stability
CC       of the protein. {ECO:0000269|PubMed:12529333}.
CC   -!- PTM: Ubiquitinated; leading to proteasome-mediated degradation.
CC       Ubiquitination and sumoylation take place at different sites.
CC       {ECO:0000269|PubMed:12529333}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NCOA1 is a cause
CC       of rhabdomyosarcoma. Translocation t(2;2)(q35;p23) with PAX3
CC       generates the NCOA1-PAX3 oncogene consisting of the N-terminus
CC       part of PAX3 and the C-terminus part of NCOA1. The fusion protein
CC       acts as a transcriptional activator. Rhabdomyosarcoma is the most
CC       common soft tissue carcinoma in childhood, representing 5-8% of
CC       all malignancies in children. {ECO:0000269|PubMed:15313887}.
CC   -!- SIMILARITY: Belongs to the SRC/p160 nuclear receptor coactivator
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA64187.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAC50305.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ncoa1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U59302; AAC50631.1; -; mRNA.
DR   EMBL; AJ000881; CAA04371.1; -; mRNA.
DR   EMBL; AJ000882; CAA04372.1; -; mRNA.
DR   EMBL; U90661; AAB50242.1; -; mRNA.
DR   EMBL; EF660499; ABS29266.1; -; Genomic_DNA.
DR   EMBL; AC013459; AAX93184.1; -; Genomic_DNA.
DR   EMBL; AC093798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471053; EAX00746.1; -; Genomic_DNA.
DR   EMBL; BC111533; AAI11534.1; -; mRNA.
DR   EMBL; BC111534; AAI11535.1; -; mRNA.
DR   EMBL; U40396; AAC50305.1; ALT_INIT; mRNA.
DR   EMBL; U19179; AAA64187.1; ALT_INIT; mRNA.
DR   EMBL; AY633656; AAT47737.1; -; mRNA.
DR   CCDS; CCDS1712.1; -. [Q15788-1]
DR   CCDS; CCDS1713.1; -. [Q15788-2]
DR   CCDS; CCDS42660.1; -. [Q15788-3]
DR   PIR; A57620; A57620.
DR   PIR; PC4363; PC4363.
DR   PIR; PC4364; PC4364.
DR   RefSeq; NP_003734.3; NM_003743.4. [Q15788-1]
DR   RefSeq; NP_671756.1; NM_147223.2. [Q15788-2]
DR   RefSeq; NP_671766.1; NM_147233.2. [Q15788-3]
DR   RefSeq; XP_005264682.1; XM_005264625.1. [Q15788-1]
DR   RefSeq; XP_005264683.1; XM_005264626.1. [Q15788-3]
DR   RefSeq; XP_005264685.1; XM_005264628.1. [Q15788-2]
DR   RefSeq; XP_016860657.1; XM_017005168.1. [Q15788-2]
DR   RefSeq; XP_016860658.1; XM_017005169.1. [Q15788-2]
DR   UniGene; Hs.596314; -.
DR   PDB; 1FM6; X-ray; 2.10 A; B/E/V/Y=676-700.
DR   PDB; 1FM9; X-ray; 2.10 A; B/E=676-700.
DR   PDB; 1K4W; X-ray; 1.90 A; B=686-700.
DR   PDB; 1K74; X-ray; 2.30 A; B/E=676-700.
DR   PDB; 1K7L; X-ray; 2.50 A; B/D/F/H=680-700.
DR   PDB; 1KV6; X-ray; 2.70 A; C/D=686-700.
DR   PDB; 1N4H; X-ray; 2.10 A; B=686-700.
DR   PDB; 1NQ7; X-ray; 1.50 A; B=687-696.
DR   PDB; 1NRL; X-ray; 2.00 A; C/D=676-700.
DR   PDB; 1P8D; X-ray; 2.80 A; C/D=676-700.
DR   PDB; 1PZL; X-ray; 2.10 A; B=687-700.
DR   PDB; 1RDT; X-ray; 2.40 A; B=676-700.
DR   PDB; 1TFC; X-ray; 2.40 A; C/D=686-700.
DR   PDB; 1U3R; X-ray; 2.21 A; C/D=630-640.
DR   PDB; 1U3S; X-ray; 2.50 A; C/D=630-640.
DR   PDB; 1X76; X-ray; 2.20 A; C/D=630-640.
DR   PDB; 1X78; X-ray; 2.30 A; C/D=630-640.
DR   PDB; 1X7B; X-ray; 2.30 A; C/D=630-640.
DR   PDB; 1X7J; X-ray; 2.30 A; C/D=630-640.
DR   PDB; 1XIU; X-ray; 2.50 A; E/F=686-700.
DR   PDB; 1XV9; X-ray; 2.70 A; E/F/G/H=685-697.
DR   PDB; 1XVP; X-ray; 2.60 A; E/F/G/H=685-697.
DR   PDB; 1YY4; X-ray; 2.70 A; C/D=630-640.
DR   PDB; 1YYE; X-ray; 2.03 A; C/D=630-640.
DR   PDB; 1ZAF; X-ray; 2.20 A; C/D=630-640.
DR   PDB; 2A3I; X-ray; 1.95 A; B=1430-1441.
DR   PDB; 2C52; NMR; -; B=920-970.
DR   PDB; 2FVJ; X-ray; 1.99 A; B=628-640.
DR   PDB; 2GTK; X-ray; 2.10 A; B=631-640.
DR   PDB; 2HBH; X-ray; 2.65 A; B=686-700.
DR   PDB; 2HC4; X-ray; 2.20 A; B=686-700.
DR   PDB; 2HCD; X-ray; 2.60 A; B=686-700.
DR   PDB; 2HFP; X-ray; 2.00 A; B=680-700.
DR   PDB; 2NPA; X-ray; 2.30 A; B/D=683-697.
DR   PDB; 2NV7; X-ray; 2.10 A; C/D=631-640.
DR   PDB; 2P54; X-ray; 1.79 A; B=686-696.
DR   PDB; 2PRG; X-ray; 2.30 A; C=623-710.
DR   PDB; 3BEJ; X-ray; 1.90 A; E/F=676-700.
DR   PDB; 3BQD; X-ray; 2.50 A; B=1429-1441.
DR   PDB; 3CTB; X-ray; 2.00 A; A/B=678-700.
DR   PDB; 3CWD; X-ray; 2.40 A; C/D=685-700.
DR   PDB; 3DCT; X-ray; 2.50 A; B=741-761.
DR   PDB; 3DCU; X-ray; 2.95 A; B=741-761.
DR   PDB; 3DR1; X-ray; 2.70 A; B=686-700.
DR   PDB; 3ET1; X-ray; 2.50 A; P/Q=681-696.
DR   PDB; 3ET3; X-ray; 1.95 A; P=680-695.
DR   PDB; 3FEI; X-ray; 2.40 A; Z=744-756.
DR   PDB; 3FEJ; X-ray; 2.01 A; B=628-640.
DR   PDB; 3FUR; X-ray; 2.30 A; H=629-640.
DR   PDB; 3FXV; X-ray; 2.26 A; B=744-756.
DR   PDB; 3G8I; X-ray; 2.20 A; Z=744-756.
DR   PDB; 3G9E; X-ray; 2.30 A; B=628-640.
DR   PDB; 3GYT; X-ray; 2.40 A; B=1429-1441.
DR   PDB; 3GYU; X-ray; 2.40 A; B=1429-1441.
DR   PDB; 3H0A; X-ray; 2.10 A; B/E=629-640.
DR   PDB; 3HC5; X-ray; 2.60 A; B=741-761.
DR   PDB; 3HC6; X-ray; 3.20 A; B=741-761.
DR   PDB; 3HVL; X-ray; 2.10 A; A/B=678-700.
DR   PDB; 3IPQ; X-ray; 2.00 A; B=676-700.
DR   PDB; 3IPS; X-ray; 2.26 A; C/D=676-700.
DR   PDB; 3IPU; X-ray; 2.40 A; C/D=676-700.
DR   PDB; 3KMR; X-ray; 1.80 A; C=686-698.
DR   PDB; 3LMP; X-ray; 1.90 A; C=686-700.
DR   PDB; 3OKH; X-ray; 2.50 A; B=744-757.
DR   PDB; 3OKI; X-ray; 2.00 A; B/D=744-757.
DR   PDB; 3OLF; X-ray; 1.90 A; B/D=744-757.
DR   PDB; 3OLL; X-ray; 1.50 A; C/D=683-701.
DR   PDB; 3OLS; X-ray; 2.20 A; C/D=683-701.
DR   PDB; 3OMK; X-ray; 1.90 A; B/D=744-757.
DR   PDB; 3OMM; X-ray; 2.10 A; B/D=744-757.
DR   PDB; 3OMO; X-ray; 2.21 A; C/D=683-701.
DR   PDB; 3OMP; X-ray; 2.05 A; C/D=683-701.
DR   PDB; 3OMQ; X-ray; 1.97 A; C/D=683-701.
DR   PDB; 3OOF; X-ray; 2.29 A; B/D=744-757.
DR   PDB; 3OOK; X-ray; 2.29 A; B/D=744-757.
DR   PDB; 3P88; X-ray; 2.95 A; B=745-755.
DR   PDB; 3P89; X-ray; 2.30 A; B=745-755.
DR   PDB; 3QT0; X-ray; 2.50 A; C=685-700.
DR   PDB; 3RUT; X-ray; 3.00 A; B=745-755.
DR   PDB; 3RUU; X-ray; 2.50 A; B=745-755.
DR   PDB; 3RVF; X-ray; 3.10 A; B=741-761.
DR   PDB; 3S9S; X-ray; 2.55 A; B=685-697.
DR   PDB; 3T03; X-ray; 2.10 A; C/D=683-700.
DR   PDB; 3UU7; X-ray; 2.20 A; F/G=686-698.
DR   PDB; 3UUA; X-ray; 2.05 A; F/G=686-698.
DR   PDB; 3UUD; X-ray; 1.60 A; C/D=686-698.
DR   PDB; 3V9Y; X-ray; 2.10 A; B=686-700.
DR   PDB; 3VN2; X-ray; 2.18 A; C=685-700.
DR   PDB; 4DK7; X-ray; 2.45 A; B/D=745-756.
DR   PDB; 4DK8; X-ray; 2.75 A; B/D=745-756.
DR   PDB; 4DM6; X-ray; 1.90 A; E/F=676-700.
DR   PDB; 4DM8; X-ray; 2.30 A; C/D=676-700.
DR   PDB; 4DQM; X-ray; 2.75 A; B/D=1432-1441.
DR   PDB; 4F9M; X-ray; 1.90 A; C=686-700.
DR   PDB; 4FGY; X-ray; 2.84 A; B=686-696.
DR   PDB; 4G1D; X-ray; 2.90 A; B=686-700.
DR   PDB; 4G1Y; X-ray; 2.85 A; B=686-700.
DR   PDB; 4G1Z; X-ray; 2.50 A; B=686-700.
DR   PDB; 4G20; X-ray; 2.90 A; B=686-700.
DR   PDB; 4G21; X-ray; 2.90 A; B=686-700.
DR   PDB; 4G2H; X-ray; 2.50 A; B=686-700.
DR   PDB; 4HEE; X-ray; 2.50 A; Y=676-700.
DR   PDB; 4J5X; X-ray; 2.80 A; A/B/C/D=678-700.
DR   PDB; 4JYG; X-ray; 2.35 A; F/G=686-698.
DR   PDB; 4JYH; X-ray; 2.60 A; C/G=686-698.
DR   PDB; 4JYI; X-ray; 1.90 A; F/G=686-698.
DR   PDB; 4MG5; X-ray; 2.05 A; C/D=686-698.
DR   PDB; 4MG6; X-ray; 2.10 A; C/D=686-698.
DR   PDB; 4MG7; X-ray; 2.15 A; C/D=686-698.
DR   PDB; 4MG8; X-ray; 1.85 A; C/D=686-698.
DR   PDB; 4MG9; X-ray; 2.00 A; F/G=686-698.
DR   PDB; 4MGA; X-ray; 1.80 A; C/D=686-698.
DR   PDB; 4MGB; X-ray; 1.85 A; C/D=686-698.
DR   PDB; 4MGC; X-ray; 2.15 A; F/G=686-698.
DR   PDB; 4MGD; X-ray; 1.90 A; F/G=686-698.
DR   PDB; 4RUJ; X-ray; 2.35 A; B=686-700.
DR   PDB; 4RUP; X-ray; 2.75 A; B=686-700.
DR   PDB; 4TUZ; X-ray; 1.90 A; F/G=686-698.
DR   PDB; 4TV1; X-ray; 1.85 A; C/D=686-698.
DR   PDB; 4UDA; X-ray; 2.03 A; B=1427-1441.
DR   PDB; 4UDB; X-ray; 2.36 A; B=1427-1441.
DR   PDB; 4Y29; X-ray; 1.98 A; B=1432-1441.
DR   PDB; 5A86; X-ray; 2.25 A; C/D=682-698.
DR   PDB; 5AVI; X-ray; 2.70 A; B/D=676-700.
DR   PDB; 5AVL; X-ray; 2.80 A; B=676-700.
DR   PDB; 5AZT; X-ray; 3.45 A; C=683-697.
DR   PDB; 5DSH; X-ray; 2.95 A; B=685-700.
DR   PDB; 5DV3; X-ray; 2.75 A; B=685-700.
DR   PDB; 5DV6; X-ray; 2.80 A; B=685-700.
DR   PDB; 5DV8; X-ray; 2.75 A; B=685-700.
DR   PDB; 5DVC; X-ray; 2.30 A; B=685-700.
DR   PDB; 5DWL; X-ray; 2.20 A; B=685-700.
DR   PDB; 5E7V; X-ray; 2.40 A; B=686-700.
DR   PDB; 5HJS; X-ray; 1.72 A; C/D=676-700.
DR   PDB; 5L7E; X-ray; 1.86 A; B=1432-1441.
DR   PDB; 5L7G; X-ray; 2.01 A; B=1432-1441.
DR   PDB; 5L7H; X-ray; 1.84 A; B=1432-1441.
DR   PDBsum; 1FM6; -.
DR   PDBsum; 1FM9; -.
DR   PDBsum; 1K4W; -.
DR   PDBsum; 1K74; -.
DR   PDBsum; 1K7L; -.
DR   PDBsum; 1KV6; -.
DR   PDBsum; 1N4H; -.
DR   PDBsum; 1NQ7; -.
DR   PDBsum; 1NRL; -.
DR   PDBsum; 1P8D; -.
DR   PDBsum; 1PZL; -.
DR   PDBsum; 1RDT; -.
DR   PDBsum; 1TFC; -.
DR   PDBsum; 1U3R; -.
DR   PDBsum; 1U3S; -.
DR   PDBsum; 1X76; -.
DR   PDBsum; 1X78; -.
DR   PDBsum; 1X7B; -.
DR   PDBsum; 1X7J; -.
DR   PDBsum; 1XIU; -.
DR   PDBsum; 1XV9; -.
DR   PDBsum; 1XVP; -.
DR   PDBsum; 1YY4; -.
DR   PDBsum; 1YYE; -.
DR   PDBsum; 1ZAF; -.
DR   PDBsum; 2A3I; -.
DR   PDBsum; 2C52; -.
DR   PDBsum; 2FVJ; -.
DR   PDBsum; 2GTK; -.
DR   PDBsum; 2HBH; -.
DR   PDBsum; 2HC4; -.
DR   PDBsum; 2HCD; -.
DR   PDBsum; 2HFP; -.
DR   PDBsum; 2NPA; -.
DR   PDBsum; 2NV7; -.
DR   PDBsum; 2P54; -.
DR   PDBsum; 2PRG; -.
DR   PDBsum; 3BEJ; -.
DR   PDBsum; 3BQD; -.
DR   PDBsum; 3CTB; -.
DR   PDBsum; 3CWD; -.
DR   PDBsum; 3DCT; -.
DR   PDBsum; 3DCU; -.
DR   PDBsum; 3DR1; -.
DR   PDBsum; 3ET1; -.
DR   PDBsum; 3ET3; -.
DR   PDBsum; 3FEI; -.
DR   PDBsum; 3FEJ; -.
DR   PDBsum; 3FUR; -.
DR   PDBsum; 3FXV; -.
DR   PDBsum; 3G8I; -.
DR   PDBsum; 3G9E; -.
DR   PDBsum; 3GYT; -.
DR   PDBsum; 3GYU; -.
DR   PDBsum; 3H0A; -.
DR   PDBsum; 3HC5; -.
DR   PDBsum; 3HC6; -.
DR   PDBsum; 3HVL; -.
DR   PDBsum; 3IPQ; -.
DR   PDBsum; 3IPS; -.
DR   PDBsum; 3IPU; -.
DR   PDBsum; 3KMR; -.
DR   PDBsum; 3LMP; -.
DR   PDBsum; 3OKH; -.
DR   PDBsum; 3OKI; -.
DR   PDBsum; 3OLF; -.
DR   PDBsum; 3OLL; -.
DR   PDBsum; 3OLS; -.
DR   PDBsum; 3OMK; -.
DR   PDBsum; 3OMM; -.
DR   PDBsum; 3OMO; -.
DR   PDBsum; 3OMP; -.
DR   PDBsum; 3OMQ; -.
DR   PDBsum; 3OOF; -.
DR   PDBsum; 3OOK; -.
DR   PDBsum; 3P88; -.
DR   PDBsum; 3P89; -.
DR   PDBsum; 3QT0; -.
DR   PDBsum; 3RUT; -.
DR   PDBsum; 3RUU; -.
DR   PDBsum; 3RVF; -.
DR   PDBsum; 3S9S; -.
DR   PDBsum; 3T03; -.
DR   PDBsum; 3UU7; -.
DR   PDBsum; 3UUA; -.
DR   PDBsum; 3UUD; -.
DR   PDBsum; 3V9Y; -.
DR   PDBsum; 3VN2; -.
DR   PDBsum; 4DK7; -.
DR   PDBsum; 4DK8; -.
DR   PDBsum; 4DM6; -.
DR   PDBsum; 4DM8; -.
DR   PDBsum; 4DQM; -.
DR   PDBsum; 4F9M; -.
DR   PDBsum; 4FGY; -.
DR   PDBsum; 4G1D; -.
DR   PDBsum; 4G1Y; -.
DR   PDBsum; 4G1Z; -.
DR   PDBsum; 4G20; -.
DR   PDBsum; 4G21; -.
DR   PDBsum; 4G2H; -.
DR   PDBsum; 4HEE; -.
DR   PDBsum; 4J5X; -.
DR   PDBsum; 4JYG; -.
DR   PDBsum; 4JYH; -.
DR   PDBsum; 4JYI; -.
DR   PDBsum; 4MG5; -.
DR   PDBsum; 4MG6; -.
DR   PDBsum; 4MG7; -.
DR   PDBsum; 4MG8; -.
DR   PDBsum; 4MG9; -.
DR   PDBsum; 4MGA; -.
DR   PDBsum; 4MGB; -.
DR   PDBsum; 4MGC; -.
DR   PDBsum; 4MGD; -.
DR   PDBsum; 4RUJ; -.
DR   PDBsum; 4RUP; -.
DR   PDBsum; 4TUZ; -.
DR   PDBsum; 4TV1; -.
DR   PDBsum; 4UDA; -.
DR   PDBsum; 4UDB; -.
DR   PDBsum; 4Y29; -.
DR   PDBsum; 5A86; -.
DR   PDBsum; 5AVI; -.
DR   PDBsum; 5AVL; -.
DR   PDBsum; 5AZT; -.
DR   PDBsum; 5DSH; -.
DR   PDBsum; 5DV3; -.
DR   PDBsum; 5DV6; -.
DR   PDBsum; 5DV8; -.
DR   PDBsum; 5DVC; -.
DR   PDBsum; 5DWL; -.
DR   PDBsum; 5E7V; -.
DR   PDBsum; 5HJS; -.
DR   PDBsum; 5L7E; -.
DR   PDBsum; 5L7G; -.
DR   PDBsum; 5L7H; -.
DR   ProteinModelPortal; Q15788; -.
DR   SMR; Q15788; -.
DR   BioGrid; 114200; 109.
DR   DIP; DIP-30877N; -.
DR   IntAct; Q15788; 31.
DR   MINT; MINT-153305; -.
DR   STRING; 9606.ENSP00000320940; -.
DR   BindingDB; Q15788; -.
DR   ChEMBL; CHEMBL1615387; -.
DR   DrugBank; DB07119; 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL.
DR   DrugBank; DB06875; 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE.
DR   DrugBank; DB07236; 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL.
DR   DrugBank; DB07230; 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE.
DR   DrugBank; DB07724; 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid.
DR   DrugBank; DB07150; 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME.
DR   DrugBank; DB07198; 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE.
DR   DrugBank; DB06927; [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE.
DR   DrugBank; DB08915; Aleglitazar.
DR   DrugBank; DB01645; Genistein.
DR   DrugBank; DB08231; MYRISTIC ACID.
DR   GuidetoPHARMACOLOGY; 2693; -.
DR   iPTMnet; Q15788; -.
DR   PhosphoSitePlus; Q15788; -.
DR   BioMuta; NCOA1; -.
DR   DMDM; 158518533; -.
DR   EPD; Q15788; -.
DR   MaxQB; Q15788; -.
DR   PaxDb; Q15788; -.
DR   PeptideAtlas; Q15788; -.
DR   PRIDE; Q15788; -.
DR   Ensembl; ENST00000288599; ENSP00000288599; ENSG00000084676. [Q15788-2]
DR   Ensembl; ENST00000348332; ENSP00000320940; ENSG00000084676. [Q15788-1]
DR   Ensembl; ENST00000395856; ENSP00000379197; ENSG00000084676. [Q15788-3]
DR   Ensembl; ENST00000405141; ENSP00000385097; ENSG00000084676. [Q15788-2]
DR   Ensembl; ENST00000406961; ENSP00000385216; ENSG00000084676. [Q15788-1]
DR   GeneID; 8648; -.
DR   KEGG; hsa:8648; -.
DR   UCSC; uc002rfj.4; human. [Q15788-1]
DR   CTD; 8648; -.
DR   DisGeNET; 8648; -.
DR   GeneCards; NCOA1; -.
DR   HGNC; HGNC:7668; NCOA1.
DR   HPA; CAB019402; -.
DR   HPA; HPA070213; -.
DR   HPA; HPA070520; -.
DR   MIM; 602691; gene.
DR   neXtProt; NX_Q15788; -.
DR   OpenTargets; ENSG00000084676; -.
DR   PharmGKB; PA31470; -.
DR   eggNOG; ENOG410IQ5S; Eukaryota.
DR   eggNOG; ENOG410XPF9; LUCA.
DR   GeneTree; ENSGT00530000063109; -.
DR   HOVERGEN; HBG052583; -.
DR   InParanoid; Q15788; -.
DR   KO; K09101; -.
DR   OMA; QITPQPP; -.
DR   OrthoDB; EOG091G00US; -.
DR   PhylomeDB; Q15788; -.
DR   TreeFam; TF332652; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-159418; Recycling of bile acids and salts.
DR   Reactome; R-HSA-192105; Synthesis of bile acids and bile salts.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SignaLink; Q15788; -.
DR   SIGNOR; Q15788; -.
DR   ChiTaRS; NCOA1; human.
DR   EvolutionaryTrace; Q15788; -.
DR   GeneWiki; Nuclear_receptor_coactivator_1; -.
DR   GenomeRNAi; 8648; -.
DR   PRO; PR:Q15788; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000084676; -.
DR   ExpressionAtlas; Q15788; baseline and differential.
DR   Genevisible; Q15788; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; IMP:CAFA.
DR   GO; GO:0050681; F:androgen receptor binding; NAS:UniProtKB.
DR   GO; GO:0017162; F:aryl hydrocarbon receptor binding; IPI:CAFA.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IPI:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IDA:UniProtKB.
DR   GO; GO:0033142; F:progesterone receptor binding; IEA:Ensembl.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046965; F:retinoid X receptor binding; IEA:Ensembl.
DR   GO; GO:0001012; F:RNA polymerase II regulatory region DNA binding; IEA:Ensembl.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; NAS:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0015721; P:bile acid and bile salt transport; TAS:Reactome.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IBA:GO_Central.
DR   GO; GO:1904017; P:cellular response to Thyroglobulin triiodothyronine; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0043967; P:histone H4 acetylation; IEA:Ensembl.
DR   GO; GO:0021854; P:hypothalamus development; IEA:Ensembl.
DR   GO; GO:0030522; P:intracellular receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0060713; P:labyrinthine layer morphogenesis; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0060179; P:male mating behavior; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045925; P:positive regulation of female receptivity; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0000435; P:positive regulation of transcription from RNA polymerase II promoter by galactose; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:2001038; P:regulation of cellular response to drug; IEA:Ensembl.
DR   GO; GO:0002155; P:regulation of thyroid hormone mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IDA:UniProtKB.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 1.
DR   Gene3D; 1.10.287.1070; -; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR010011; DUF1518.
DR   InterPro; IPR028819; NCOA1.
DR   InterPro; IPR009110; Nuc_rcpt_coact.
DR   InterPro; IPR014920; Nuc_rcpt_coact_Ncoa-typ.
DR   InterPro; IPR017426; Nuclear_rcpt_coactivator.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR014935; SRC/p160_LXXLL.
DR   PANTHER; PTHR10684; PTHR10684; 1.
DR   PANTHER; PTHR10684:SF8; PTHR10684:SF8; 1.
DR   Pfam; PF07469; DUF1518; 2.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF08815; Nuc_rec_co-act; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF08832; SRC-1; 1.
DR   SMART; SM01151; DUF1518; 2.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00091; PAS; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   SUPFAM; SSF69125; SSF69125; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Acyltransferase;
KW   Alternative splicing; Chromosomal rearrangement; Complete proteome;
KW   Isopeptide bond; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2   1441       Nuclear receptor coactivator 1.
FT                                /FTId=PRO_0000094400.
FT   DOMAIN       23     80       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   DOMAIN      109    180       PAS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   REGION      361    567       Interaction with STAT3.
FT                                {ECO:0000269|PubMed:11773079}.
FT   REGION      781    988       Interaction with CREBBP.
FT   MOTIF        46     50       LXXLL motif 1.
FT   MOTIF       112    116       LXXLL motif 2.
FT   MOTIF       633    637       LXXLL motif 3.
FT   MOTIF       690    694       LXXLL motif 4.
FT   MOTIF       749    753       LXXLL motif 5.
FT   MOTIF       913    917       LXXLL motif 6.
FT   MOTIF      1435   1439       LXXLL motif 7.
FT   COMPBIAS    389    682       Ser-rich.
FT   COMPBIAS   1053   1138       Gln-rich.
FT   SITE        867    868       Breakpoint for translocation to form
FT                                PAX3-NCOA1 oncogene.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      22     22       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     372    372       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10660621}.
FT   MOD_RES     395    395       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10660621}.
FT   MOD_RES     517    517       Phosphoserine.
FT                                {ECO:0000269|PubMed:10660621}.
FT   MOD_RES     558    558       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P70365}.
FT   MOD_RES     569    569       Phosphoserine.
FT                                {ECO:0000269|PubMed:10660621}.
FT   MOD_RES     698    698       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1033   1033       Phosphoserine.
FT                                {ECO:0000269|PubMed:10660621}.
FT   MOD_RES    1073   1073       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:P70365}.
FT   MOD_RES    1091   1091       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:P70365}.
FT   MOD_RES    1124   1124       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:P70365}.
FT   MOD_RES    1131   1131       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:P70365}.
FT   MOD_RES    1179   1179       Phosphothreonine.
FT                                {ECO:0000269|PubMed:10660621}.
FT   MOD_RES    1185   1185       Phosphoserine.
FT                                {ECO:0000269|PubMed:10660621}.
FT   MOD_RES    1372   1372       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    732    732       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:12529333}.
FT   CROSSLNK    774    774       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:12529333}.
FT   VAR_SEQ    1385   1385       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:8754792}.
FT                                /FTId=VSP_011738.
FT   VAR_SEQ    1386   1441       QVQQVQVFADVQCTVNLVGGDPYLNQPGPLGTQKPTSGPQT
FT                                PQAQQKSLLQQLLTE -> DKKTEEFFSVVTTD (in
FT                                isoform 2). {ECO:0000303|PubMed:11831720,
FT                                ECO:0000303|PubMed:15313887,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9427757}.
FT                                /FTId=VSP_011739.
FT   VARIANT     457    457       Q -> K (in dbSNP:rs1049015).
FT                                {ECO:0000269|PubMed:7481822,
FT                                ECO:0000269|PubMed:8754792,
FT                                ECO:0000269|PubMed:9575154}.
FT                                /FTId=VAR_019768.
FT   VARIANT     466    466       N -> K (in dbSNP:rs1049016).
FT                                {ECO:0000269|PubMed:7481822,
FT                                ECO:0000269|PubMed:8754792,
FT                                ECO:0000269|PubMed:9575154}.
FT                                /FTId=VAR_019769.
FT   VARIANT     474    474       S -> P (in dbSNP:rs1049018).
FT                                {ECO:0000269|PubMed:7481822,
FT                                ECO:0000269|PubMed:8754792,
FT                                ECO:0000269|PubMed:9575154}.
FT                                /FTId=VAR_019770.
FT   VARIANT     591    591       I -> T (in dbSNP:rs1049020).
FT                                {ECO:0000269|PubMed:7481822,
FT                                ECO:0000269|PubMed:8754792,
FT                                ECO:0000269|PubMed:9575154}.
FT                                /FTId=VAR_019771.
FT   VARIANT     685    685       E -> A (in dbSNP:rs1049021).
FT                                {ECO:0000269|PubMed:7481822,
FT                                ECO:0000269|PubMed:8754792,
FT                                ECO:0000269|PubMed:9575154}.
FT                                /FTId=VAR_019772.
FT   VARIANT     794    794       P -> A (in dbSNP:rs1049025).
FT                                {ECO:0000269|PubMed:7481822}.
FT                                /FTId=VAR_019773.
FT   VARIANT     999    999       S -> F (in dbSNP:rs1049032).
FT                                {ECO:0000269|PubMed:7481822,
FT                                ECO:0000269|PubMed:8754792,
FT                                ECO:0000269|PubMed:9575154}.
FT                                /FTId=VAR_019774.
FT   VARIANT    1154   1154       M -> T (in dbSNP:rs1049038).
FT                                {ECO:0000269|PubMed:7481822,
FT                                ECO:0000269|PubMed:8754792,
FT                                ECO:0000269|PubMed:9575154}.
FT                                /FTId=VAR_019775.
FT   VARIANT    1238   1238       V -> I (in dbSNP:rs56099330).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038832.
FT   VARIANT    1272   1272       P -> S (in dbSNP:rs1804645).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_034882.
FT   MUTAGEN     636    637       LL->AA: Slightly affects interactions
FT                                with steroid receptors. Abolishes
FT                                interactions with steroid receptors; when
FT                                associated with A-693; A-694; A-752 and
FT                                A-753. {ECO:0000269|PubMed:9427757}.
FT   MUTAGEN     693    694       LL->AA: Slightly affects interactions
FT                                with steroid receptors. Abolishes
FT                                interactions with steroid receptors; when
FT                                associated with A-636; A-637; A-752 and
FT                                A-753. {ECO:0000269|PubMed:9427757}.
FT   MUTAGEN     732    732       K->R: Abolishes sumoylation; when
FT                                associated with R-774.
FT                                {ECO:0000269|PubMed:12529333}.
FT   MUTAGEN     752    753       LL->AA: Slightly affects interactions
FT                                with steroid receptors. Abolishes
FT                                interactions with steroid receptors; when
FT                                associated with A-636; A-637; A-693 and
FT                                A-694. {ECO:0000269|PubMed:9427757}.
FT   MUTAGEN     774    774       K->R: Abolishes sumoylation; when
FT                                associated with R-732.
FT                                {ECO:0000269|PubMed:12529333}.
FT   MUTAGEN     800    800       K->R: Does not affect sumoylation of the
FT                                protein. {ECO:0000269|PubMed:12529333}.
FT   MUTAGEN     846    846       K->R: Does not affect sumoylation of the
FT                                protein. {ECO:0000269|PubMed:12529333}.
FT   MUTAGEN    1378   1378       K->R: Does not affect sumoylation of the
FT                                protein. {ECO:0000269|PubMed:12529333}.
FT   CONFLICT   1035   1035       Missing (in Ref. 10; AAT47737).
FT                                {ECO:0000305}.
FT   CONFLICT   1370   1370       Q -> H (in Ref. 9; AAA64187).
FT                                {ECO:0000305}.
FT   CONFLICT   1382   1382       D -> G (in Ref. 10; AAT47737).
FT                                {ECO:0000305}.
FT   CONFLICT   1435   1435       L -> R (in Ref. 3; AAB50242).
FT                                {ECO:0000305}.
FT   HELIX       632    638       {ECO:0000244|PDB:2FVJ}.
FT   HELIX       684    686       {ECO:0000244|PDB:5HJS}.
FT   HELIX       688    695       {ECO:0000244|PDB:1NQ7}.
FT   HELIX       747    754       {ECO:0000244|PDB:3OLF}.
FT   TURN        924    926       {ECO:0000244|PDB:2C52}.
FT   HELIX       929    941       {ECO:0000244|PDB:2C52}.
FT   HELIX       945    947       {ECO:0000244|PDB:2C52}.
FT   HELIX       952    954       {ECO:0000244|PDB:2C52}.
FT   TURN        958    962       {ECO:0000244|PDB:2C52}.
FT   STRAND      964    966       {ECO:0000244|PDB:2C52}.
FT   HELIX      1434   1440       {ECO:0000244|PDB:5L7H}.
SQ   SEQUENCE   1441 AA;  156757 MW;  25EF6F389489121E CRC64;
     MSGLGDSSSD PANPDSHKRK GSPCDTLASS TEKRRREQEN KYLEELAELL SANISDIDSL
     SVKPDKCKIL KKTVDQIQLM KRMEQEKSTT DDDVQKSDIS SSSQGVIEKE SLGPLLLEAL
     DGFFFVVNCE GRIVFVSENV TSYLGYNQEE LMNTSVYSIL HVGDHAEFVK NLLPKSLVNG
     VPWPQEATRR NSHTFNCRML IHPPDEPGTE NQEACQRYEV MQCFTVSQPK SIQEDGEDFQ
     SCLICIARRL PRPPAITGVE SFMTKQDTTG KIISIDTSSL RAAGRTGWED LVRKCIYAFF
     QPQGREPSYA RQLFQEVMTR GTASSPSYRF ILNDGTMLSA HTKCKLCYPQ SPDMQPFIMG
     IHIIDREHSG LSPQDDTNSG MSIPRVNPSV NPSISPAHGV ARSSTLPPSN SNMVSTRINR
     QQSSDLHSSS HSNSSNSQGS FGCSPGSQIV ANVALNQGQA SSQSSNPSLN LNNSPMEGTG
     ISLAQFMSPR RQVTSGLATR PRMPNNSFPP NISTLSSPVG MTSSACNNNN RSYSNIPVTS
     LQGMNEGPNN SVGFSASSPV LRQMSSQNSP SRLNIQPAKA ESKDNKEIAS ILNEMIQSDN
     SSSDGKPLDS GLLHNNDRLS DGDSKYSQTS HKLVQLLTTT AEQQLRHADI DTSCKDVLSC
     TGTSNSASAN SSGGSCPSSH SSLTERHKIL HRLLQEGSPS DITTLSVEPD KKDSASTSVS
     VTGQVQGNSS IKLELDASKK KESKDHQLLR YLLDKDEKDL RSTPNLSLDD VKVKVEKKEQ
     MDPCNTNPTP MTKPTPEEIK LEAQSQFTAD LDQFDQLLPT LEKAAQLPGL CETDRMDGAV
     TSVTIKSEIL PASLQSATAR PTSRLNRLPE LELEAIDNQF GQPGTGDQIP WTNNTVTAIN
     QSKSEDQCIS SQLDELLCPP TTVEGRNDEK ALLEQLVSFL SGKDETELAE LDRALGIDKL
     VQGGGLDVLS ERFPPQQATP PLIMEERPNL YSQPYSSPSP TANLPSPFQG MVRQKPSLGT
     MPVQVTPPRG AFSPGMGMQP RQTLNRPPAA PNQLRLQLQQ RLQGQQQLIH QNRQAILNQF
     AATAPVGINM RSGMQQQITP QPPLNAQMLA QRQRELYSQQ HRQRQLIQQQ RAMLMRQQSF
     GNNLPPSSGL PVQMGNPRLP QGAPQQFPYP PNYGTNPGTP PASTSPFSQL AANPEASLAN
     RNSMVSRGMT GNIGGQFGTG INPQMQQNVF QYPGAGMVPQ GEANFAPSLS PGSSMVPMPI
     PPPQSSLLQQ TPPASGYQSP DMKAWQQGAI GNNNVFSQAV QNQPTPAQPG VYNNMSITVS
     MAGGNTNVQN MNPMMAQMQM SSLQMPGMNT VCPEQINDPA LRHTGLYCNQ LSSTDLLKTE
     ADGTQQVQQV QVFADVQCTV NLVGGDPYLN QPGPLGTQKP TSGPQTPQAQ QKSLLQQLLT
     E
//
